Anogenital warts: a new way of solving the common problem of urology (results of long-term follow-up)


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Aim To evaluate the effectiveness of combined use of the imiquimod 5% cream and vaccination against human papillomavirus (HPV) using a quadrivalent recombinant vaccine to achieve long-term clinical remission of chronic HPV infection manifested by anogenital warts. Material and methods The study comprised 36 patients, including 22 men, aged 26.4±4.1 years, who had from 1 to 5 anogenital warts. Participants of the study were vaccinated by quadrivalent recombinant vaccine under a 3-dose scheme 0-2-6 months co-administered with imiquimod 5% cream three times per week up to 16 weeks. The follow-up period was 2 years. Results Complete disappearance of genital warts within 1 year from baseline was observed in 34 (94.4%) patients. Two patients with anogenital warts after 1 year were treated for 1 year 3 months and 1 year and 4 months with Solcoderm which lead to the complete disappearance of genital warts. There were no recurrences of genital warts during the 2 years of follow-up. Conclusion Vaccination with a recombinant quadrivalent vaccine concurrently with using imiquimod 5% cream results in prolonged clinical remission of chronic HPV infection manifested by anogenital warts in at least 94.4% of the cases (2 year follow-up).

Texto integral

Acesso é fechado

Sobre autores

A. Protasov

Samara State Medical University

Email: crosss82@maiI.ru
PhD, Associate Professor at the Department of General and Clinical Microbiology, Immunology and Allergology, SamSMU, Allergist-Immunologist at the Clinic SamSMU

I. Lipatov

Samara State Medical University

Email: i.lipatoff2012@yandex.ru

M. Kostinov

I.I. Mechnikov Research Institute of Vaccines and Sera

Email: vaccine@bk.ru

Yu. Tezikov

Samara State Medical University

Email: yra.75@inbox.ru

A. Shmit’ko

I.I. Mechnikov Research Institute of Vaccines and Sera

Email: violadellanna@gmail.com

D. Pakhomov

I.I. Mechnikov Research Institute of Vaccines and Sera

Email: vaccine@bk.ru

D. Blagovidov

I.I. Mechnikov Research Institute of Vaccines and Sera

Email: vaccine@bk.ru

A. Zhestkov

Samara State Medical University

Email: avzhestkov2015@yandex.ru

A. Ryzhov

I.I. Mechnikov Research Institute of Vaccines and Sera

Email: vaccine@bk.ru

E. Vekhova

Samara Regional Center for Prevention and Control of AIDS and Infectious Diseases

Bibliografia

  1. Howell-Jones R., de Silva N., Akpan M., Oakeshott P., Carder C., Coupland L. et al. Prevalence of human papillomavirus (HPV) infections in sexually active adolescents and young women in England, prior to widespread HPV immunization. Vaccine. 2012;30(26):3867-3875. doi: 10.1016/j.vaccine.2012.04.006.
  2. Гомберг М.А., Соловьев А.М. Лечение бородавок и остроконечных кондилом - просто и эффективно. Медицинский совет. 2011;5-6:60-65
  3. Кузнецова Ю.Н. Лечение остроконечных кондилом аногенитальной области препаратом Солкодерм. Уральский медицинский журнал. 2005;3:2-3
  4. Аполихина И.А., Салех Ю.В. Современные возможности в лечении остроконечных кондилом. Акушерство и гинекология. 2011;5:134-136
  5. Неймарк Б.А., Кондратьева Ю.С., Зологина В.С., Торбик Д.В. Эффективность комбинированного лечения папилломавирусной инфекции. Урология. 2015;2:39-42
  6. Hengge U.R., Benninghoff B., Ruzicka T., Gooset M. Topical immunomodulators - progress towards treating inflammation, infection, and cancer. Lancet Infectious Diseases. 2001;1(3):189-198. DOI: http://dx.doi.org/10.1016/S1473-3099(01)00095-0.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2016

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies